Literature DB >> 3172429

Relapse to cocaine abuse after initiating desipramine treatment.

R D Weiss1.   

Abstract

Three cocaine abusers who had been abstinent for one to six months relapsed to cocaine use soon after beginning desipramine hydrochloride therapy. The antidepressant treatment was begun for different reasons in each case. All three patients developed what has been termed the early tricyclic jitteriness syndrome. This reaction may have stimulated conditioned craving for cocaine because of the similarity between this syndrome and cocaine intoxication. Since desipramine is being used to reduce cocaine craving, it is important to recognize this paradoxical increase in craving as a potential adverse effect of desipramine.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3172429

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  5 in total

Review 1.  Pharmacotherapies for cocaine dependence.

Authors:  G O'Leary; R D Weiss
Journal:  Curr Psychiatry Rep       Date:  2000-12       Impact factor: 5.285

2.  Effects of the putative dopamine autoreceptor antagonists (+)-AJ 76 and (+)-UH 232 on the discriminative stimulus properties of cocaine.

Authors:  P M Callahan; M F Piercey; K A Cunningham
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

3.  Time course of transient behavioral depression and persistent behavioral sensitization in relation to regional brain monoamine concentrations during amphetamine withdrawal in rats.

Authors:  P E Paulson; D M Camp; T E Robinson
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

Review 4.  Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management.

Authors:  Sean S O'Sullivan; Andrew H Evans; Andrew J Lees
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

5.  Monoamine reuptake inhibitors enhance the discriminative state induced by cocaine in the rat.

Authors:  K A Cunningham; P M Callahan
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.